TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38152893

Group type: EXPERIMENTAL
Intervention: Blood monocyte count and frequency of the classical monocyte subtype
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Monocyte subtype profiles
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Monocyte count
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Monocyte transcriptome analyses and plasma metabolomes
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Monocyte frequency and count assessment
Number of subjects: 672
Study: 38152962

Group type: EXPERIMENTAL
Intervention: Reteplase 12+12 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Reteplase 18+18 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Reteplase (both dosages)
Number of subjects: 180
Study: 38153225

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38153320

Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat treatment courses with Zuranolone
Number of subjects: 0
Study: 38153339

Group type: EXPERIMENTAL
Intervention: AI-based Bristol stool scale (AI-BSS) via Dieta app
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dieta app
Number of subjects: 46
Study: 38153429

Group type: EXPERIMENTAL
Intervention: Ligamentous vaginal repair of POP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Good anatomical prolapse repair
Number of subjects: 0
Study: 38153510

Group type: EXPERIMENTAL
Intervention: ScRp + i-PRF
Number of subjects: 17

Group type: COMPARATOR
Intervention: ScRp + saline
Number of subjects: 17
Study: 38153568

Group type: EXPERIMENTAL
Intervention: High step (≥30,000 steps/week)
Number of subjects: 283
Study: 38153624

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 100 mg daily
Number of subjects: 0
Study: 38153735

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Zolpidem plus BT
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Zolpidem plus trazodone
Number of subjects: 211
Study: 38153868

Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 665

Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 665
Study: 38154074

Group type: EXPERIMENTAL
Intervention: Prazosin 2.5 mg/day for 7 days, then 5 mg/day for 21 days
Number of subjects: 15
Study: 38154083

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin threshold 7.0 g/dL)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conservative transfusion strategy (hemoglobin threshold 5.5 g/dL)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 38154287

Group type: EXPERIMENTAL
Intervention: SPACE-Standard (12 weekly telehealth sessions)
Number of subjects: 68

Group type: COMPARATOR
Intervention: SPACE-Light (bibliotherapy plus 4 telehealth sessions over 12 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: SPACE-Light
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both SPACE-Standard and SPACE-Light
Number of subjects: 68
Study: 38154599

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus regular bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular bupivacaine alone
Number of subjects: 60
Study: 38154616

Group type: EXPERIMENTAL
Intervention: Ivermectin (0.3-0.4 mg/kg, orally on an empty stomach once daily for three days)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 1030
Study: 38154621

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 238

Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 238
Study: 38154770

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Clomiphene + Metformin
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 333
Study: 38154825

Group type: EXPERIMENTAL
Intervention: Participants with IBD
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 38154894

Group type: EXPERIMENTAL
Intervention: Non-ischaemic heart preservation (NIHP)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Ischaemic cold static storage (ICSS)
Number of subjects: 202
Study: 38154893

Group type: EXPERIMENTAL
Intervention: Presence of multiple lower genital tract microorganisms in pregnancy
Number of subjects: 600
Study: 38154895

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) with culturally tailored diabetes self-management education and support (DSMES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Culturally tailored diabetes self-management education and support (DSMES) with blinded continuous glucose monitoring (CGM)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management education and support (DSMES) with RT-CGM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Culturally tailored diabetes self-management education and support (DSMES)
Number of subjects: 100
Study: 38154899

Group type: EXPERIMENTAL
Intervention: Assessment of shoulder symptoms and anatomical variants/imaging abnormalities
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Concordance assessment between shoulder symptoms, function, and imaging abnormalities
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Identification of determinants of symptoms, function, and imaging abnormalities
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of shoulder complaints over 5 years
Number of subjects: 600
Study: 38154902

Group type: EXPERIMENTAL
Intervention: Optimal prophylactic regimens for postoperative nausea/vomiting (PONV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supraoptimal prophylactic regimens for postoperative nausea/vomiting (PONV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One of five different single-injection techniques/combination of techniques for regional/neuraxial analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group for regional/neuraxial analgesia (not specified)
Number of subjects: 0
Study: 38155060

Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg) alone (cohort 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg) with lirilumab (240 mg) (cohort 2)
Number of subjects: 43
Study: 38155164

Group type: EXPERIMENTAL
Intervention: Multimedia-based hormone therapy information program (HTIP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study: 38155223

Group type: EXPERIMENTAL
Intervention: Handheld ultrasound-assisted CSE analgesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Palpation-guided CSE analgesia
Number of subjects: 84
Study: 38155459

Group type: EXPERIMENTAL
Intervention: Lower MMP-2 levels in blood samples taken 6 hours after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower MMP-3 levels in blood samples taken 6 hours after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher MMP-3 levels in LBA samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower MMP-3 levels in blood samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower MMP-7 levels in blood samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower MMP-9 levels in LBA samples
Number of subjects: 0
Study: 38155462

Group type: EXPERIMENTAL
Intervention: Suction-based neuroprotection device
Number of subjects: 298

Group type: COMPARATOR
Intervention: Filtration-based device or standard aortic cannula
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Postoperative delirium
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: DWI-ISD
Number of subjects: 298
Study: 38155512

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy for borderline resectable pancreatic cancer
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy for locally advanced pancreatic cancer
Number of subjects: 188

Group type: COMPARATOR
Intervention: Resection
Number of subjects: 188
Study: 38155665

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 339

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 38155668

Group type: EXPERIMENTAL
Intervention: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'ARDS' mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vibroacoustic pulmonary therapy using the 'VibroLung' device in 'Pneumonia' mode
Number of subjects: 60
Study: 38155784

Group type: EXPERIMENTAL
Intervention: EndoPatch (endovascular double-disc implant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional endovascular treatment techniques
Number of subjects: 0
Study: 38156046

Group type: EXPERIMENTAL
Intervention: DTG/TDF/3TC
Number of subjects: 613

Group type: COMPARATOR
Intervention: EFV400/TDF/3TC
Number of subjects: 613
Study: 38156073

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation (tSCS) with various parameters including cathode electrode placement (T7/8, T9/10, T11/12, L1/2), stimulation frequency (30, 60 Hz), current amplitudes (0-120 mA), waveform (mono- and biphasic), pulse width (1000 μs), and carrier frequency (0, 10 kHz).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation (tSCS)
Number of subjects: 0
Study: 38156522

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38156524

Group type: EXPERIMENTAL
Intervention: Colonic PASH detected on biopsies using whole-mount immunostaining.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Visual and automated analyses of polysomnography signals.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Probable Arizona PD stage classifications based on sleep and wake EEG features.
Number of subjects: 43
Study: 38156550

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 3146
Study: 38156592

Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Clinical judgment
Number of subjects: 1432
Study: 38156601

Group type: EXPERIMENTAL
Intervention: Low-dose quadruple therapy (LDQT)
Number of subjects: 62
Study: 38156792

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 252
Study: 38157050

Group type: EXPERIMENTAL
Intervention: Pre-prandial plasma LEAP2 concentration in OW/OB individuals
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pre-prandial plasma ghrelin concentration in OW/OB individuals
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pre-prandial plasma LEAP2 concentration
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Postprandial plasma LEAP2 concentration in females with OW/OB
Number of subjects: 44
Study: 38157190

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax (560 mg ibrutinib and 400 mg venetoclax after a 5-week ramp-up from 20 mg, once daily for up to 104 weeks)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 13
Study: 38157193

Group type: EXPERIMENTAL
Intervention: Decitabine with Carboplatin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 12
Study: 38157227

Group type: EXPERIMENTAL
Intervention: Isoquercetin (IQ)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 38157234

Group type: EXPERIMENTAL
Intervention: GetActive+ mind-body activity intervention
Number of subjects: 30
Study: 38157237

Group type: EXPERIMENTAL
Intervention: Culturally tailored advance care planning (ACP) intervention (MY WAY)
Number of subjects: 155
Study: 38157348

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg IV QID for seven days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg (single dose)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 77
Study: 38157499

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21)
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90)
Number of subjects: 6100
Study: 38157500

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 8058

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 8058
Study: 38157653

Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DKK-1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: cathepsin-D
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GDF-15 and cathepsin-D
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study: 38157974

Group type: EXPERIMENTAL
Intervention: Scan with a rubber dam in place
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scan without a rubber dam
Number of subjects: 30
Study: 38157981

Group type: EXPERIMENTAL
Intervention: BAT (Basophil Activation Test) in consumers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SPT (Skin Prick Test) to raw egg in consumers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OVA-sIgE in consumers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EW-sIgE in consumers
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BAT in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EW-sIgE in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SPT to EW in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sIgE to egg white in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sIgE to ovalbumin in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sIgE to ovomucoid in avoiders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sIgG4 to all egg allergens in consumers
Number of subjects: 100
Study: 38157986

Group type: EXPERIMENTAL
Intervention: 400 μg folic acid supplement
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0 μg folic acid supplement (control)
Number of subjects: 24
Study: 38157987

Group type: EXPERIMENTAL
Intervention: Advice on moderation in alcohol consumption
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Advice on abstention from alcohol consumption
Number of subjects: 10000
Study: 38158089

Group type: EXPERIMENTAL
Intervention: Octreotide 40-mg long-acting release intramuscular every 28 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard of care (including endoscopic therapy)
Number of subjects: 62
Study: 38158159

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg every 8 weeks
Number of subjects: 1891

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg T&E
Number of subjects: 1891

Group type: COMPARATOR
Intervention: aflibercept 2.0 mg every 8 weeks
Number of subjects: 1891
Study: 38158385

Group type: EXPERIMENTAL
Intervention: CNN-1
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CNN-2
Number of subjects: 66
Study: 38158450

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation plus inspiratory muscle training (PR + IMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 30
Study: 38158583

Group type: EXPERIMENTAL
Intervention: Basal insulin therapy using a connected insulin pen
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Three-step model for evaluating adherence
Number of subjects: 103
Study: 38158919

Group type: EXPERIMENTAL
Intervention: Albuminuria (mild: 10-29 mg/g, moderate/severe: ≥30 mg/g)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD) diagnosis based on KDIGO criteria
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Albuminuria as a marker of atherosclerosis burden
Number of subjects: 74
Study: 38159003

Group type: EXPERIMENTAL
Intervention: Chitotriosidase (CHIT) level in plasma on the first day of hospitalization
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Chitotriosidase (CHIT) level in deceased patients
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Chitotriosidase (CHIT) level > 171 nmol/h/mL
Number of subjects: 347
Study: 38159159

Group type: EXPERIMENTAL
Intervention: Periodontitis in Alzheimer's patients (Stage II and Stage III)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Periodontitis in Alzheimer's patients (Stage III)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Periodontitis and Alzheimer's disease progression
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AD Stage II-Stage III, periodontitis, and age
Number of subjects: 90
Study: 38159266

Group type: EXPERIMENTAL
Intervention: Lorpucitinib (30 mg daily, 30 mg every 12 hours, or 75 mg every 12 hours)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tofacitinib (5 mg every 12 hours)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lorpucitinib (75 mg single dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lorpucitinib (all doses)
Number of subjects: 36
Study: 38159337

Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02) with hypofractionated radiotherapy (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zotiraciclib (TG02) with temozolomide (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 0
Study: 38159652

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 153

Group type: COMPARATOR
Intervention: Anticonvulsants
Number of subjects: 153
Study: 38159809

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 623
Study: 38159908

Group type: EXPERIMENTAL
Intervention: Nivolumab treatment
Number of subjects: 60
Study: 38159938

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by platinum based chemotherapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 400
Study: 38159941

Group type: EXPERIMENTAL
Intervention: active tDCS combined with Pilates-based exercises
Number of subjects: 36

Group type: COMPARATOR
Intervention: sham tDCS combined with Pilates-based exercises
Number of subjects: 36
Study: 38159942

Group type: EXPERIMENTAL
Intervention: Usual care combined with peer support (three individual sessions at 1, 3 and 5 months with a peer helper)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Usual care combined with peer support
Number of subjects: 60
Study: 38159943

Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 0
Study: 38159946

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of early organ damage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital follow-up mechanism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishment of biological sample bank
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of early structural and functional cardiovascular organ damage
Number of subjects: 0
Study: 38159950

Group type: EXPERIMENTAL
Intervention: Additional contact X-ray brachytherapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Extended observation period followed by optional transanal local excision
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 168
Study: 38159958

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention, consisting of 10 sessions.
Number of subjects: 20
Study: 38160017

Group type: EXPERIMENTAL
Intervention: Ultrasound estimation in the paramedian sagittal oblique (PSO) view
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ultrasound estimation in the transverse median (TM) view
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Image quality of ligamentum flavum and posterior dura mater in PSO view
Number of subjects: 55
Study: 38160047

Group type: EXPERIMENTAL
Intervention: Individualised yoga
Number of subjects: 125

Group type: COMPARATOR
Intervention: iPad control
Number of subjects: 125
Study: 38160049

Group type: EXPERIMENTAL
Intervention: HDM sublingual immunotherapy (SLIT)-tablets
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 38160050

Group type: EXPERIMENTAL
Intervention: Cumulative occupational exposure to gases/fumes
Number of subjects: 2042

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: Cumulative occupational exposure (gases/fumes)
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: Occupational exposures (in women)
Number of subjects: 2042

Group type: COMPARATOR
Intervention: Smoking (in women)
Number of subjects: 2042
Study: 38160357

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study: 38160619

Group type: EXPERIMENTAL
Intervention: PROTAC technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controllable PROTACs
Number of subjects: 0
Study: 38160756

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day) for 180 days
Number of subjects: 12
Study: 38160802

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: WFPB diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: FAFH costs for baseline diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: FAFH costs for DASH diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FAFH costs for WFPB diet
Number of subjects: 15
Study: 38160805

Group type: EXPERIMENTAL
Intervention: Pea protein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 15
Study: 38160885

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Baseline abnormal ReHo
Number of subjects: 98
Study: 38160916

Group type: EXPERIMENTAL
Intervention: Real-time tracking/gating during MRgRT
Number of subjects: 79